CB1 Receptor Modulation Against Parkinson’s disease in Rats

CB1 Receptor Modulation Against Parkinson’s disease in Rats


Marketed By :  LAP LAMBERT Academic Publishing   Sold By :  Kamal Books International  
Delivery in :  10-12 Business Days

₹ 3,718

Availability: Out of stock


Delivery :

5% Cashback on all Orders paid using MobiKwik Wallet T&C

Free Krispy Kreme Voucher on all Orders paid using UltraCash Wallet T&C
Product Out of Stock Subscription

(Notify me when this product is back in stock)

  • Product Description

Recently, the controversial role of cannabinoid receptors was reported in the pathophysiology of PD. In the present study we have investigated the role of CB1 receptors in motor behaviour. Repeated intranigral (day 1, 7, 14) infusion of MPTP was done to produce stable motor deficits in rats. CB1 receptor agonist, Noladin ether and antagonist AM 251, was administered alone or in combination in MPTP-infused rats. Grip strength, spontaneous locomotor activity and narrow beam walk tests were used to access motor behaviours. Oxidative stress and pro-inflammatory cytokine levels were determined in striatal brain homogenates. MPTP-infused rats showed stable motor deficit and elevation in oxidative stress and cytokine levels. AM 251 attenuated MPYP-induced motor dysfunction, oxidative stress and neuroinflammation in rats. Conversely, noladin ether synergized MPTP- mediated neurotoxicity, which was significantly attenuated by AM 251 pre-treatment. The above results suggests that sustained activation of CB1 receptors may play a crucial role in the development motor dysfunction and thus CB1 receptor blockade would be therapeutic in PD.

Product Specifications
SKU :COC60491
Country of ManufactureIndia
Product BrandLAP LAMBERT Academic Publishing
Product Packaging InfoBox
In The Box1 Piece
Product First Available On ClickOnCare.com2015-08-05
0 Review(s)